Ridgeback Biotherapeutics LP
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Ridgeback Biotherapeutics LP
Strides has pushed back US revenue guidance of $225m-$250m by a year to FY23 amid price erosion and substantial competition in the market. Meanwhile, the firm’s CEO says Merck’s molnupiravir and Pfizer’s Paxlovid are not seen impacting COVID-19 vaccine uptake as boosters and immunization for travel will drive continued demand. The Indian company expects to book Sputnik Light sales from Q4.
US FDA seems poised to authorize the oral COVID treatment, but panel discussion will likely highlight the limitations of the antiviral.
The EMA is going all out to maximize coverage of the EU population with both vaccines and treatments for COVID-19.
Orphan drugs and COVID-19 products are among the latest filings under review by the European Medicines Agency for potential pan-EU approval.
- In Vitro Diagnostics